Business Wire

GN-CORPORATION

14.3.2022 07:09:12 CET | Business Wire | Press release

Share
Nichi GLOW: Japanese Beta-Glucan, in Children With Autism Spectrum Disorder, Improves Behavior, Sleep, and Gut Microbiome in a Clinical Study

In the first such report, children with Autism spectrum disorder (ASD) showed improvement in behaviour, learning skills and sleep, after oral consumption of AFO-202 strain of black yeast Aureobasidium Pullulans produced Beta 1,3 -1,6 glucan (Nichi GLOW), published in BMJ Neurology Open (http://dx.doi.org/10.1136/bmjno-2021-000203 ). Beneficial reconstitution of gut microbiota was also reported with Nichi GLOW, which is unique from other beta glucans by its source, production method, and purity.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220313005031/en/

Autism is a neurodevelopmental disorder affecting 1 in 44 children in the developed world, with multiple causes and varying severity of manifestation. These children are more likely to develop neurodegenerative diseases in later life. In the study, Nichi GLOW intake improved CARS score and communication skills (https://www.youtube.com/watch?v=reJOjBMKSg4 ). Nichi GLOW controlled enterobacteria, a gut microbiome producing harmful proteins like curli and amyloid, leading to Alpha-synuclein misfolding and aggregation in the neurons, a cause of the disease (https://doi.org/10.1101/2021.10.26.21265505 ). Synucleinopathy spreading through gut-brain-axis to the brain, might cause Parkinson’s or Dementia, therefore, it’s worth studying the prophylaxis of Nichi Glucan range of products in neurodegenerative conditions, as microglia activation is one of the mechanisms of their action in brain (https://doi.org/10.1016/j.jns.2021.117554 ), says Dr. Raghavan, the principal investigator.

The findings were presented in a webinar commemorating Autism Sunday (https://www.ncrmniche.org/autismsunday2022/proceedings/index.html ), organized by Jesuit Antonyraj memorial Inter-disciplinary Center for Advanced Recovery and Education (JAICARE). Research conducted in Japan unraveled the hidden potentials (https://doi.org/10.1101/2021.08.05.21261640 ), of this ß-glucan; thanks to a wholesome ecosystem in Japan aiding development of novel solutions, which together with the trans-world inter-disciplinary network of healthcare expertise of GN Corp have made this path-breaking feat possible, commented the scientists. https://sponsored.bloomberg.com/article/jco/japan-where-high-tech-meets-high-value-foreign-direct-investment

Nichi Glucan range of products were approved as food additives in Japan in 1996 and don’t contain any commonly notified allergens. They are unique, being produced as an exo-polysaccharide by novel strains of Aureobasidium Pullulans in a GMP certified facility in Japan and exported in different brands: Nichi-GLOW, Neu-REFIX, Nichi Glucan & Nichi Glucan-REFIX ; not intended to diagnose, treat, cure, or prevent any disease & approval status may vary between countries. Publications are meant for academic and research initiative purposes; not to be construed as medical advice. Physicians’ advice is recommended for specific health queries.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Grindr Nominates Three New Directors to Its Board of Directors30.4.2026 23:16:00 CEST | Press release

Grindr Inc. (NYSE: GRND), the Global Gayborhood in Your Pocket™, today announced the nomination of Rob Solomon, Lisa Gersh, and Fadi Hanna to stand for election to its Board of Directors at the Annual Meeting of Shareholders on June 2, 2026. Rob Solomon is a deeply seasoned technology CEO and operator in consumer internet and marketplaces. He has held CEO and COO roles at scaled platforms including GoFundMe, Groupon, and Kayak-predecessor SideStep, and is currently CEO of leading electric aviation company H55. Lisa Gersh is a CEO and long-tenured public company director with deep experience across consumer brands, media, and commerce. She has served on the Hasbro (NASDAQ: HAS) board since 2010 and has led businesses including Oxygen Media, GOOP, and Alexander Wang. Fadi Hanna is Chief Risk Officer at Bloomberg L.P., overseeing enterprise risk across the organization. He previously worked at J.P. Morgan and has served on the board of Immigration Equality. “Over the last few years, we bu

The Empire State Building Celebrates 95 Years as the ‘World’s Most Famous Building’30.4.2026 22:42:00 CEST | Press release

New Tickets, Exclusive Offers, and Special Anniversary Programs Kick off May 1 The Empire State Building (ESB), the “World’s Most Famous Building,” will celebrate its 95th anniversary on May 1, 2026, with new offers at the Empire State Building Observation Deck, a special birthday tower lighting display, and a slate of celebrations to honor its legacy and future. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430693323/en/ The Empire State Building Celebrates 95 Years as the ‘World’s Most Famous Building’ “The Empire State Building celebrates its 95th anniversary, still the ‘World’s Most Famous Building,’ a modernized, sustainability leader as technologically advanced today as the day she was completed, and the winner of #1 Top Attraction in the United States in Tripadvisor’s Travelers’ Choice Awards for 2026,” said Anthony E. Malkin, chairman and CEO of Empire State Realty Trust. Anniversary Offerings and Experiences To

MRM Health’s Lead Candidate MH002 Granted Fast Track Designation by U.S. FDA for the Treatment of Mild-to-Moderate Ulcerative Colitis30.4.2026 22:17:00 CEST | Press release

Recognizes the potential of MH002 to address a serious medical condition with high unmet need Enables accelerated development and increased FDA interactions to streamline review process MRM Health will be presenting at upcoming Digestive Disease Week (DDW) 2026, taking place from May 2nd – May 5th in Chicago, IL, USA MRM Health, a clinical-stage biopharmaceutical company developing therapeutics for immune-mediated diseases, which unlock the power of the microbiome to restore immune balance, today announced that MH002, the Company’s lead rationally designed Live Biotherapeutic Product (LBP) candidate, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of mild-to-moderate ulcerative colitis (UC). MH002 today is the most advanced LBP targeting inflammatory bowel disease (IBD)-specific mechanisms and is composed of a rationally designed microbial consortium of six well-characterized commensal strains. The FDA’s Fast Track is a process d

Rimini Street Announces Fiscal First Quarter 2026 Financial and Operating Results30.4.2026 22:01:00 CEST | Press release

First Quarter Financial Highlights Include: Remaining Performance Obligations (RPO) of $643.6 million, up 16.4% year over year Adjusted Calculated Billings of $92.2 million, up 22.9% year over year Adjusted Annualized Recurring Revenue (ARR) of $388.0 million, up 5.0% year over year Rimini Street, Inc., (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and Agentic AI ERP innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced results for the fiscal first quarter ended March 31, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430598629/en/ Rimini Street Announces Fiscal First Quarter 2026 Financial and Operating Results “Our first quarter results reflect continued growth and accelerating momentum in our core Rimini Support™ business as organizations turn to the proven Rimini Smart Path™ to execute their global E

OpenAI and Yubico Partner to Bring Custom Phishing-Resistant YubiKeys to OpenAI Users30.4.2026 19:13:00 CEST | Press release

New strategic, long-term partnership with OpenAI delivers the gold standard of hardware-backed passkeys to the AI ecosystem Yubico (NASDAQ STOCKHOLM: YUBICO), the pioneer of phishing-resistant authentication and creator of the YubiKey, the gold standard of security keys, today announced an industry-first collaboration with OpenAI, the creator of ChatGPT. Beginning today, people can purchase a new 2-pack set of custom YubiKeys as part of OpenAI’s Advanced Account Security program – enabling them to secure their ChatGPT accounts with security keys, containing the strongest hardware-backed passkeys. Specifically designed for security-conscious users who are at increased risk of targeted digital attacks, the set includes a YubiKey C NFC for tap-to-authenticate on mobile, and a low profile YubiKey C Nano that stays in a port for everyday laptop use – both packed with modern authentication features for the highest level of protection. With OpenAI already using YubiKeys internally to protect

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye